Your browser doesn't support javascript.
loading
Clinical Characteristics and Treatment Outcomes in Children, Adolescents, and Young-adults with Hodgkin's Lymphoma: a KPHOG Lymphoma Working-party, Multicenter, Retrospective Study.
Lee, Jae Min; Choi, Jung Yoon; Hong, Kyung Taek; Kang, Hyoung Jin; Shin, Hee Young; Baek, Hee Jo; Kook, Hoon; Kim, Seongkoo; Lee, Jae Wook; Chung, Nack Gyun; Cho, Bin; Cho, Seok Goo; Park, Kyung Mi; Yang, Eu Jeen; Lim, Young Tak; Suh, Jin Kyung; Kang, Sung Han; Kim, Hyery; Koh, Kyung Nam; Im, Ho Joon; Seo, Jong Jin; Cho, Hee Won; Ju, Hee Young; Lee, Ji Won; Yoo, Keon Hee; Sung, Ki Woong; Koo, Hong Hoe; Park, Kyung Duk; Hah, Jeong Ok; Kim, Min Kyoung; Han, Jung Woo; Hahn, Seung Min; Lyu, Chuhl Joo; Shim, Ye Jee; Kim, Heung Sik; Do, Young Rok; Yoo, Jae Won; Lim, Yeon Jung; Jeon, In Sang; Chueh, Hee Won; Oh, Sung Yong; Choi, Hyoung Soo; Park, Jun Eun; Lee, Jun Ah; Park, Hyeon Jin; Park, Byung Kiu; Kim, Soon Ki; Lim, Jae Young; Park, Eun Sil; Park, Sang Kyu.
Afiliación
  • Lee JM; Department of Pediatrics, Yeungnam University College of Medicine, Daegu, Korea.
  • Choi JY; Department of Pediatrics, Seoul National University College of Medicine, Seoul, Korea.
  • Hong KT; Seoul National University Cancer Institute, Seoul, Korea.
  • Kang HJ; Department of Pediatrics, Seoul National University College of Medicine, Seoul, Korea.
  • Shin HY; Seoul National University Cancer Institute, Seoul, Korea.
  • Baek HJ; Department of Pediatrics, Seoul National University College of Medicine, Seoul, Korea.
  • Kook H; Seoul National University Cancer Institute, Seoul, Korea.
  • Kim S; Department of Pediatrics, Seoul National University College of Medicine, Seoul, Korea.
  • Lee JW; Seoul National University Cancer Institute, Seoul, Korea.
  • Chung NG; Department of Pediatrics, Chonnam National University Hwasun Hospital, Chonnam National University Medical School, Gwangju, Korea.
  • Cho B; Department of Pediatrics, Chonnam National University Hwasun Hospital, Chonnam National University Medical School, Gwangju, Korea. hoonkook@chonnam.ac.kr.
  • Cho SG; Department of Pediatrics, College of Medicine, The Catholic University of Korea, Seoul, Korea.
  • Park KM; Department of Pediatrics, College of Medicine, The Catholic University of Korea, Seoul, Korea.
  • Yang EJ; Department of Pediatrics, College of Medicine, The Catholic University of Korea, Seoul, Korea. cngped@catholic.ac.kr.
  • Lim YT; Department of Pediatrics, College of Medicine, The Catholic University of Korea, Seoul, Korea.
  • Suh JK; Department of Hematology, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.
  • Kang SH; Department of Pediatrics, Pusan National University School of Medicines, Yangsan, Korea.
  • Kim H; Department of Pediatrics, Pusan National University School of Medicines, Yangsan, Korea.
  • Koh KN; Department of Pediatrics, Pusan National University School of Medicines, Yangsan, Korea.
  • Im HJ; Division of Pediatric Hematology/Oncology, Department of Pediatrics, Asan Medical Center Children's Hospital, University of Ulsan College of Medicine, Seoul, Korea.
  • Seo JJ; Division of Pediatric Hematology/Oncology, Department of Pediatrics, Asan Medical Center Children's Hospital, University of Ulsan College of Medicine, Seoul, Korea.
  • Cho HW; Division of Pediatric Hematology/Oncology, Department of Pediatrics, Asan Medical Center Children's Hospital, University of Ulsan College of Medicine, Seoul, Korea.
  • Ju HY; Division of Pediatric Hematology/Oncology, Department of Pediatrics, Asan Medical Center Children's Hospital, University of Ulsan College of Medicine, Seoul, Korea.
  • Lee JW; Division of Pediatric Hematology/Oncology, Department of Pediatrics, Asan Medical Center Children's Hospital, University of Ulsan College of Medicine, Seoul, Korea.
  • Yoo KH; Division of Pediatric Hematology/Oncology, Department of Pediatrics, Asan Medical Center Children's Hospital, University of Ulsan College of Medicine, Seoul, Korea.
  • Sung KW; Department of Pediatrics, Samsung Medical Center, School of Medicine, Sungkyunkwan University, Seoul, Korea.
  • Koo HH; Department of Pediatrics, Samsung Medical Center, School of Medicine, Sungkyunkwan University, Seoul, Korea.
  • Park KD; Department of Pediatrics, Samsung Medical Center, School of Medicine, Sungkyunkwan University, Seoul, Korea.
  • Hah JO; Department of Pediatrics, Samsung Medical Center, School of Medicine, Sungkyunkwan University, Seoul, Korea.
  • Kim MK; Department of Pediatrics, Samsung Medical Center, School of Medicine, Sungkyunkwan University, Seoul, Korea.
  • Han JW; Department of Pediatrics, Samsung Medical Center, School of Medicine, Sungkyunkwan University, Seoul, Korea.
  • Hahn SM; Department of Pediatrics and Research Institute of Clinical Medicine of Jeonbuk National University-Jeonbuk National University Hospital, Jeonbuk National University Medical School, Jeonju, Korea.
  • Lyu CJ; Department of Pediatrics, Daegu Fatima Hospital, Daegu, Korea.
  • Shim YJ; Department of Internal Medicine, Yeungnam University College of Medicine, Daegu, Korea.
  • Kim HS; Division of Pediatric Hematology and Oncology, Department of Pediatrics, Yonsei University College of Medicine, Seoul, Korea.
  • Do YR; Division of Pediatric Hematology and Oncology, Department of Pediatrics, Yonsei University College of Medicine, Seoul, Korea.
  • Yoo JW; Division of Pediatric Hematology and Oncology, Department of Pediatrics, Yonsei University College of Medicine, Seoul, Korea.
  • Lim YJ; Department of Pediatrics, Keimyung University School of Medicine, Keimyung University Dongsan Medical Center, Daegu, Korea.
  • Jeon IS; Department of Pediatrics, Keimyung University School of Medicine, Keimyung University Dongsan Medical Center, Daegu, Korea.
  • Chueh HW; Division of Hemato-oncology, Department of Internal Medicine, Keimyung University School of Medicine, Daegu, Korea.
  • Oh SY; Department of Pediatrics, Chungnam National University College of Medicine, Daejeon, Korea.
  • Choi HS; Department of Pediatrics, Chungnam National University College of Medicine, Daejeon, Korea.
  • Park JE; Department of Pediatrics, Gachon University Gil Medical Center, Incheon, Korea.
  • Lee JA; Department of Pediatrics, Dong-A University College of Medicine, Busan, Korea.
  • Park HJ; Department of Hematology, Dong-A University Hospital, Busan, Korea.
  • Park BK; Department of Pediatrics, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea.
  • Kim SK; Department of Pediatrics, Ajou University School of Medicine, Suwon, Korea.
  • Lim JY; Center for Pediatric Oncology, Research Institute and Hospital, National Cancer Center, Goyang, Korea.
  • Park ES; Center for Pediatric Oncology, Research Institute and Hospital, National Cancer Center, Goyang, Korea.
  • Park SK; Center for Pediatric Oncology, Research Institute and Hospital, National Cancer Center, Goyang, Korea.
J Korean Med Sci ; 35(46): e393, 2020 Nov 30.
Article en En | MEDLINE | ID: mdl-33258329
BACKGROUND: Hodgkin's lymphoma (HL) constitutes 10%-20% of all malignant lymphomas and has a high cure rate (5-year survival, around 90%). Recently, interest has increased concerning preventing secondary complications (secondary cancer, endocrine disorders) in long-term survivors. We aimed to study the epidemiologic features and therapeutic outcomes of HL in children, adolescents, and young adults in Korea. METHODS: We performed a multicenter, retrospective study of 224 patients aged < 25 years diagnosed with HL at 22 participating institutes in Korea from January 2007 to August 2016. RESULTS: A higher percentage of males was diagnosed at a younger age. Nodular sclerosis histopathological HL subtype was most common, followed by mixed cellularity subtype. Eighty-one (36.2%), 101 (45.1%), and 42 (18.8%) patients were classified into low, intermediate, and high-risk groups, respectively. Doxorubicin, bleomycin, vinblastine, dacarbazine was the most common protocol (n = 102, 45.5%). Event-free survival rate was 86.0% ± 2.4%, while five-year overall survival (OS) rate was 96.1% ± 1.4%: 98.7% ± 1.3%, 97.7% ± 1.6%, and 86.5% ± 5.6% in the low, intermediate, and high-risk groups, respectively (P = 0.021). Five-year OS was worse in patients with B-symptoms, stage IV disease, high-risk, splenic involvement, extra-nodal lymphoma, and elevated lactate dehydrogenase level. In multivariate analysis, B-symptoms and extra-nodal involvement were prognostic factors for poor OS. Late complications of endocrine disorders and secondary malignancy were observed in 17 and 6 patients, respectively. CONCLUSION: This is the first study on the epidemiology and treatment outcomes of HL in children, adolescents, and young adults in Korea. Future prospective studies are indicated to develop therapies that minimize treatment toxicity while maximizing cure rates in children, adolescents, and young adults with HL.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Enfermedad de Hodgkin / Antineoplásicos Tipo de estudio: Etiology_studies / Guideline / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Adolescent / Adult / Child / Child, preschool / Female / Humans / Infant / Male / Newborn País/Región como asunto: Asia Idioma: En Revista: J Korean Med Sci Asunto de la revista: MEDICINA Año: 2020 Tipo del documento: Article Pais de publicación: Corea del Sur
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Enfermedad de Hodgkin / Antineoplásicos Tipo de estudio: Etiology_studies / Guideline / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Adolescent / Adult / Child / Child, preschool / Female / Humans / Infant / Male / Newborn País/Región como asunto: Asia Idioma: En Revista: J Korean Med Sci Asunto de la revista: MEDICINA Año: 2020 Tipo del documento: Article Pais de publicación: Corea del Sur